Stanford-StartX Fund has supported a $4m round for Imprimed, which is working on precision cancer treatments for dogs.
Imprimed, a US-based precision cancer treatment company, has secured $4m in funding from investors including the Stanford-StartX Fund, the investment vehicle for Stanford University-affiliated accelerator StartX.
Draper Associates led the round, while Murex Partners, Plug & Play Ventures also took part. The total figure includes a previously unannounced $330,000 pre-seed investment led by Plug & Play Ventures.
Imprimed exploits precision medicine technology to help veterinary oncologists identify appropriate chemotherapies for an individual dog. The company is initially focusing…
